Epidemiology and Clinical Impact of Mycoplasma pneumoniae in an Italian Pediatric Center: An Observational Study from 2017 to 2024
Authors:
- 17 September 2025
- journal article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 45 (2) , 132-139
Abstract
Background: Mycoplasma pneumoniae (MP) is a common cause of lower respiratory tract infections in children. During the COVID-19 pandemic, a marked decline in MP infections was observed, with a delayed resurgence reported in some European countries. This study aimed to assess the epidemiologic trends and clinical features of MP infections in a pediatric tertiary care academic hospital in Italy from 2017 to 2024. Methods: We conducted a retrospective, single-center study including immunocompetent patients 30 days to 17 years of age, hospitalized with confirmed MP infection. Clinical, laboratory, and radiologic data were analyzed across 3 periods: prepandemic (2017–2019), pandemic (2020–2022) and postpandemic (2023–2024). Statistical analyses were performed to compare incidence and clinical characteristics over time. Results: Of 303 included patients, 130 were hospitalized prepandemic and 148 postpandemics. The proportion of MP among acute respiratory infection hospitalizations nearly doubled, from 3.2% in 2019 to 6.1% in 2024. Despite the higher incidence, the need for respiratory support remained stable (25.7% overall; P = 0.3), the pediatric intensive care admissions were rare and unchanged (2.0% vs. 2.0%, P = 1.0) and median hospital stay was consistent across both periods (5 days, interquartile range 4–8; P = 0.803). Conclusions: MP incidence increased significantly postpandemic, and clinical severity remained comparable to prepandemic levels. Ongoing epidemiologic surveillance is essential to better understand infection dynamics and to guide effective clinical management strategies.Keywords
This publication has 37 references indexed in Scilit:
- Analysis of the characteristics of mixed infections with Mycoplasma pneumoniae in childrenScientific Reports, 2025
- Mycoplasma pneumoniae incidence, phenotype, and severity in children and adolescents in Denmark before, during, and after the COVID-19 pandemic: a nationwide multicentre population-based cohort studyThe Lancet Regional Health - Europe, 2024
- Post-COVID-19-pandemic changes and clinical characteristics of invasive group a streptococcal infections from 2015 to 2023Infection, 2024
- Posicionamiento de la Sociedad Española de Infectología Pediátrica sobre el diagnóstico y tratamiento de la infección por Mycoplasma pneumoniaeAnales de Pediatría, 2024
- Resurgence of Mycoplasma pneumonia by macrolide-resistant epidemic clones in ChinaThe Lancet Microbe, 2024
- Invasive group A streptococcal infections in children and adolescents in Denmark during 2022–23 compared with 2016–17 to 2021–22: a nationwide, multicentre, population-based cohort studyThe Lancet Child & Adolescent Health, 2023
- Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictionsThe Lancet Microbe, 2023
- Mycoplasma pneumoniae: gone forever?The Lancet Microbe, 2023
- Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a systematic analysisThe Lancet Global Health, 2019
- Community-Acquired Pneumonia Requiring Hospitalization among U.S. ChildrenNew England Journal of Medicine, 2015